Lisa Ricciardi, president and CEO of Cognition Therapeutics CGTX was just lately a visitor on Benzinga’s All-Entry.
Cognition Therapeutics is a neuroscience firm that’s growing oral drugs to deal with neurodegenerative issues, with current breakthroughs within the remedy of dementia with Lewy our bodies (DLB) and Alzheimer’s.
The corporate says its drug candidate, CT1812, confirmed very promising outcomes from its just lately accomplished section 2 trial. The drug will now progress to section 3.
Watch the complete interview right here:
Featured picture by Rod Long on Unsplash.
This put up comprises sponsored content material. This content material is for informational functions solely and never supposed to be investing recommendation.
Market Information and Information dropped at you by Benzinga APIs
© 2025 Benzinga.com. Benzinga doesn’t present funding recommendation. All rights reserved.
